2. Signaling Pathways
  3. Immunology/Inflammation
  4. PD-1/PD-L1

PD-1/PD-L1

PD-1/Programmed death-ligand 1

PD-1/PD-L1

Related Products

PDF 0.7 MB

Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell checkpoint and plays a central role in regulating T cell exhaustion. PD-1 is activated by the engagement of its ligands PDL-1 or PDL-2. PD-1 receptor delivers inhibitory checkpoint signals to activated T cells upon binding to its ligands PD-L1 and PD-L2 expressed on antigen-presenting cells and cancer cells, resulting in suppression of T-cell effector function and tumor immune evasion. Inhibiting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway is an attractive strategy for tumor immunotherapy.

PD-1 is expressed on activated T cells, B cells, monocytes, dendritic cells (DCs), regulatory T cells (Tregs), and natural killer T cells (NKT). It is a member of a family of immunoglobulin domain (Ig) co-receptors that modify the outcome of activation of the T cell receptor by an antigen-presenting cell (APC) or infected target cell. PD-L1 is widely and constitutively expressed on both hematopoietic and nonhematopoietic cells; e.g., naive T and B cells, vascular endothelial cells, and pancreatic islet cells, whereas PD-L2 is exclusively and inducibly expressed on professional APCs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-149617
    CYP51/PD-L1-IN-4
    		Inhibitor
    CYP51/PD-L1-IN-4 (compound 14a-2) is a potent dual-target (CYP51/PD-L1) inhibitor, with IC50 values of 0.17 and 0.021 μM, respectively. CYP51/PD-L1-IN-4 exhibits excellent antifungal and antidrug-resistant fungal activity in vitro. CYP51/PD-L1-IN-4 can be used for fungal infections research.
    CYP51/PD-L1-IN-4
  • HY-162519
    LZFPN-90
    		Inhibitor
    LZFPN-90 (LZ90) is a dual NAMPT/PD-L1 targeting compound. LZFPN-90 inhibits PD-1/PD-L1 interaction and NAMPT activity. LZFPN-90 inhibits cell growth in a NAMPT-dependent manner and blocks the cell cycle, subsequently inducing apoptosis. LZFPN-90 exerted target-dependent antitumor activities, affecting metabolic processes and the immune system.
    LZFPN-90
  • HY-158052
    PD-1/PD-L1 antagonist 1
    		Antagonist
    PD-1/PD-L1 antagonist 1 (Compound A5) is an antagonist for programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) interaction, with an IC50 of 23.78 nM.
    PD-1/PD-L1 antagonist 1
  • HY-145773
    PD-1/PD-L1-IN-22
    		Inhibitor
    PD-1/PD-L1-IN-22 (Example 2) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-22 blocks PD-1/PD-L1 with the IC50 of 0.732 μM. PD-1/PD-L1-IN-22 can be used for the research of cancers, infectious diseases and autoimmune diseases.
    PD-1/PD-L1-IN-22
  • HY-145768
    PD-1/PD-L1-IN-18
    		Inhibitor
    PD-1/PD-L1-IN-18 (Compound L31) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-18 blocks PD-1/PD-L1 with the IC50 of 1.054 μM. Antitumor Activity.
    PD-1/PD-L1-IN-18
  • HY-120647
    BMS-1001
    		Inhibitor
    BMS-1001 is an orally active human PD-L1/PD-1 immune checkpoint inhibitor. BMS-1001 exhibits low-toxicity in cells. The IC50 value of BMS-1001 in a homogeneous time-resolved fluorescence (HTRF) binding assay is 2.25 nM.
    BMS-1001
  • HY-P10908
    H-20
    		Agonist
    H-20 is a PD-1 agonist. H-20 can be used in the research of chronic pain.
    H-20
  • HY-143305
    PD-1/PD-L1-IN-25
    		Inhibitor
    PD-1/PD-L1-IN-25 (compound D2) is an inhibitor of PD-1/PD-L1 interaction with an IC50 value of 16.17 nM. PD-1/PD-L1-IN-25 activates the antitumor immunity of T cells efficiently in PBMCs. PD-1/PD-L1-IN-25 can be used for the research of cancer.
    PD-1/PD-L1-IN-25
  • HY-161677
    PD-L1/CD-73-IN-1
    		Inhibitor
    PD-L1/CD-73-IN-1 (compound CC-5) is PD-L1/CD73 inhibitor with IC50 values of 6 nM and 0.773 μM to PD-L1 and CD73, respectively. PD-L1/CD-73-IN-1 inhibits tumor cell growth in vivo and in vitro.
    PD-L1/CD-73-IN-1
  • HY-144442
    PD-1/PD-L1-IN-15
    		Inhibitor
    PD-1/PD-L1-IN-15 (Compound M17) is a potent inhibitor of PD-1/PD-L1 with an IC50 value of 60.1 nM. PD-1/PD-L1-IN-15 has the potential for the research of tumor immunoresearch.
    PD-1/PD-L1-IN-15
  • HY-P991147
    Ledostomig
    		Inhibitor
    Ledostomig is an immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human netrin-5 (NTS5) and programmed death-1 (PD-1). Ledostomig is promising for research of various cancers.
    Ledostomig
  • HY-P991084
    TQB-2858
    		Inhibitor
    TQB-2858 is a bifunctional fusion protein composed of a monoclonal antibody against PD-L1 fused with the extracellular domain of TGF-β receptor. TQB-2858 has a high affinity for PD-L1, TGF-β1, and TGF-β3 and exhibited high PD-L1 target occupancy. TQB-2858 can be used for the study of osteosarcoma and alveolar soft part sarcoma (ASPS).
    TQB-2858
  • HY-162973
    PD-L1 ligand 1
    		Degrader
    PD-L1 ligand 1 is a PROTAC target protein ligand. PD-L1 ligand 1 can be used as a PD-L1 degrader.
    PD-L1 ligand 1
  • HY-B1387R
    Sulfamethoxypyridazine (Standard)
    		Inhibitor
    Sulfamethoxypyridazine (Standard) is the analytical standard of Sulfamethoxypyridazine. This product is intended for research and analytical applications. 0
    Sulfamethoxypyridazine (Standard)
  • HY-P991151
    Opamtistomig
    		Inhibitor
    Opamtistomig is a humanized immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human programmed death ligand 1 (PD-L1), CD274 and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Opamtistomig is promising for research of various solid tumors and hematological malignancies.
    Opamtistomig
  • HY-P991079
    Anti-Mouse PD-1 Antibody (D265A) Antibody (RMP1-14)
    		Inhibitor
    Anti-Mouse PD-1 Antibody (D265A) Antibody is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse PD-1.
    Anti-Mouse PD-1 Antibody (D265A) Antibody (RMP1-14)
  • HY-19745B
    BMS-202 hydrochloride
    		Inhibitor
    BMS-202 hydrochloride is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 hydrochloride binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 hydrochloride has antitumor activity.
    BMS-202 hydrochloride
  • HY-W457085
    PD-1/PD-L1-IN-29 intermediate-2
    PD-1/PD-L1-IN-29 intermediate-2 is an intermediate of PD-1/PD-L1 inhibitors and can be used to synthesize Antibody-Drug Conjugates (ADCs).
    PD-1/PD-L1-IN-29 intermediate-2
  • HY-172167
    PD-L1/HDAC-IN-1
    		Inhibitor
    PD-L1/HDAC-IN-1 (Compound 14) is the inhibitor for PD-L1 and HDAC that inhibits PD-1/PD-L1 interaction, HDAC2 and HDAC3 with IC50 of 88.10, 27.98 and 14.47 nM, respectively. PD-L1/HDAC-IN-1 exhibits slight cytotoxicity in MCF-7 (IC50=19.34 μM). PD-L1/HDAC-IN-1 upregulates the expression of PD-L1 and CXCL10, promoting anti-tumour immune response by recruiting T-cell infiltration into TME.
    PD-L1/HDAC-IN-1
  • HY-B0008R
    Sulindac (Standard)
    		Modulator
    Sulindac (Standard) is the analytical standard of Sulindac. This product is intended for research and analytical applications. Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer.
    Sulindac (Standard)
Cat. No. Product Name / Synonyms Application Reactivity